| A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation (NCT07678593) | Genfleet Therapeutics (Shanghai) Inc. | 2026-09-01 |
| A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation (NCT07668752) | Genfleet Therapeutics (Shanghai) Inc. | 2026-07-27 |
| GFH375 Monotherapy and Combination Therapy as First-Line Treatment for Advanced KRAS G12D-Mutant Non-Small Cell Lung Cancer (NCT07554859) | Genfleet Therapeutics (Shanghai) Inc. | 2026-05-20 |
| Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer (NCT07262567) | Genfleet Therapeutics (Shanghai) Inc. | 2025-12-04 |
| A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation (NCT07259590) | Genfleet Therapeutics (Shanghai) Inc. | 2025-10-21 |
| A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors (NCT07198321) | Genfleet Therapeutics (Shanghai) Inc. | 2025-09-22 |
| A Phase II Study to Evaluate GFH375 in Patients With KRAS G12D Mutant Metastatic Pancreatic Cancer (NCT07026916) | Genfleet Therapeutics (Shanghai) Inc. | 2025-08-01 |
| A Phase I Study to Evaluate GFS202A in Advanced Solid Tumor Patients With Pre-cachexia or Cachexia (NCT06898255) | Genfleet Therapeutics (Shanghai) Inc. | 2025-04-24 |
| A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations (NCT06500676) | Genfleet Therapeutics (Shanghai) Inc. | 2024-07-09 |
| A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL (NCT06375733) | Genfleet Therapeutics (Shanghai) Inc. | 2024-03-20 |
| A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) (NCT05934513) | Genfleet Therapeutics (Shanghai) Inc. | 2023-09-06 |
| A Study of GFH925 in Combination With Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation (NCT05756153) | Genfleet Therapeutics (Shanghai) Inc. | 2023-04-25 |
| A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC (NCT05386888) | Genfleet Therapeutics (Shanghai) Inc. | 2022-09-09 |
| A Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid Tumors (NCT04914286) | Genfleet Therapeutics (Shanghai) Inc. | 2021-10-20 |